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SREBP-1c Gene Silencing can Decrease Lipid Deposits in Bovine Hepatocytes Cultured in Vitro

Introduction
Fatty liver is a common multiple nutritional metabolic disease in dairy cows. The natural incidence of fatty liver is significantly higher in ruminant animals than in monogastric animals, which is explained by their special metabolic characteristics. During the early lactation period, most dairy cows experience a negative energy balance (NEB) caused by the increased demand for energy to support milk production [1] . This NEB initiates fat mobilization and a subsequent increase in the blood concentration of non-esterified fatty acid (NEFA). However, only 20% of the NEFA is used by the mammary tissue and most is absorbed by the liver. Lipid homeostasis is regulated by a family of membrane-bound transcription factors in hepatocytes. These transcription factors are designated as sterol regulatory element-binding proteins (SREBPs) and represented by three isoforms, namely SREBP-1a, SREBP-1c, and SREBP-2. SREBP-1 preferentially regulates genes involved in fatty acid and TG synthesis, and SREBP-2 primarily activates genes involved in cholesterol biosynthesis. In most animal tissues, SREBP-1c is the predominant subtype of SREBP, and it is highly expressed in adipose tissue and liver. SREBP-1c is an important nuclear transcription factor that regulates the expression of lipid metabolism genes in the liver, and it is associated with the development of fatty liver [2] [3] [4] . Studies have shown that SREBP-1c overexpression may lead to lipid metabolism disorder and cause lipid accumulation and fatty liver. However, there are many studies on over or low expression of SREBP-1c in rats and humans, while there have been few studies conducted in dairy cows [5, 6] . Studies have shown that the fat content in the liver decreased when SREBP-1c is knocked out in ob/ob mice [7] . However, the hepatic lipid metabolism in dairy cows is different from that of monogastric animals such as humans and mice. Therefore, the regulatory mechanism of SREBP-1c in relation to the incidence of fatty liver in dairy cows may be different from that of humans and mice. Therefore, we performed several related studies on cows. Bovine hepatocytes were cultured and we reduced the expression of SREBP-1c to evaluate the roles of SREBP-1c in the fatty acid metabolism of cows.
Material and Methods
Cell culture and shRNA transfection The study protocol was approved by the Ethics Committee on the Use and Care of Animals of Jilin University (Changchun, China). The caudate lobe of the liver was obtained through liver excision by surgery on a newborn calf. Hepatocytes were isolated by a modified two-step collagenase perfusion method established by our laboratory [8] . The hepatocytes density was adjusted to 2×10 6 cells/mL with adherent culture medium. The hepatocytes were seeded into a 6-well tissue culture plate (2 mL per well) and incubated at 37°C in 5% CO 2 . The medium was replaced with fresh medium every 24 h. The hepatocytes demonstrated optimum activity after being cultured for 72 h. The cells were assigned to three groups as follows: a control group (non-transfected, n=6), a negative control group (transfected with NshRNA, n=6), and four shRNA plasmids groups (transfected with shRNA1, shRNA2, shRNA3, shRNA4 respectively, n=6).
We used GenePharma software to design the shRNA sequences, which are shown in Table 1 . Four plasmids and negative controls were fluorescently labeled with FAM. The plasmids were separately transfected into hepatocytes with Lipofectamine-2000 (Invitrogen, California, USA). We used a fluorescence confocal microscope to confirm the optimum transfection time, and we then chose the most effective shRNA plasmid that could clearly lower the expression of SREBP-1c by real-time PCR.
Constructing an adenovirus low expression vector
The effective plasmid which can decrease the expression of SREBP-1c was directly subcloned into the multicloning site of the pMD-18T vector (TaKaRa Biotechnology Co., Ltd., Tokyo, Japan). The gene was then digested by KpnI/BamHI restriction enzymes and subcloned into the multicloning site of a pShuttle-Basic-EGFP vector. We then transfected this vector into 293 cells to amplify and collected the virus. The virus titer ultimately reached 10 10 PFU/ml. The recombinant adenoviruses (AD-GFP-SREBP-1c) were used to infect hepatocytes, and the multiplicity of infections (MOI) were 25, 50, 100, 150, and 200 [9] . A fluorescence 
Quantitative real-time RT-PCR
After 48h of infection, the total hepatocytes RNA were extracted by using Trizol according to manufacturer's instructions (TaKaRa Biotechnology Co., Ltd.). The RNA was reverse transcribed into cDNA by using a reverse transcription kit (TaKaRa Biotechnology Co., Ltd.) according to the manufacturer's instructions. The gene primers were designed with Primer Express software 5.0 and the resulting primers are shown in Table 2 . All primers were synthesized by Sangon (Sangon Biotech Co., Ltd., Shanghai, China). The mRNA expression levels were evaluated by quantitative real-time polymerase chain reaction (qRT-PCR) analysis with a SYBR Green QuantiTect RT-PCR Kit (TaKaRa Biotechnology Co., Ltd.). qRT-PCR was performed on a 7500 RealTime PCR System (Applied Biosystems). The mRNA expression levels were normalized to the expression of β-actin. Real-time PCR was conducted under the following conditions: an initial denaturation at 94°C for 2 min, 35 cycles of amplification (denaturation at 94°C for 10 s, annealing at 60°C for 15 s, and extension at 72°C for 30 s), and extension at 72°C for 5 min.
Protein extraction and western blot analysis
After 48h of infection, the hepatocytes were collected and lysed in lysis buffer (50 mM Tris-HCl pH 8.0, 0.15 mM NaCl, 1% Triton X-100 and 100 μM PMSF), and the protein concentrations of the lysates were measured with a BCA protein assay kit (Pierce, Rockford, US). SREBP-1c, ACC and β-actin proteins were detected. For the western blot analysis, 40 μg of total protein lysate was heated to 95°C with 4×sample buffer for 5 min and then resolved by 10% SDS-PAGE, and then the proteins were transferred onto PVDF membranes. After blocking, the membranes were incubated by using the β-actin, SREBP-1c and ACC antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA), and then Table 1 . shRNA sequences and negative control (NshRNA) for SREBP-1c Table 2 . List of primers used in this paper incubated with appropriate peroxidase-conjugated secondary antibodies (Protein technology, Chicago, USA), the resulting bands were detected using an ECL kit (Bioer, Hangzhou, China).
Detecting enzymatic activity
After infection for 48h, the total proteins in the hepatocytes were extracted using a biochemical kit (Gen Med Scientifics, USA). Then, we detected these samples according to the manufacturer's instructions. These samples were measured in at least three independent experiments.
Detecting the TG and VLDL contents
Hepatocytes and culture medium were collected after infection for 48 h. The cells were broken by an ultrasonic processor to detect the TG. The TG content was detected using a triglyceride detection kit
(Jiancheng, Nanjing, China). The VLDL content of the culture medium was detected using a VLDL detection kit (Blue Gene, Shanghai, China).
Statistics
All results are expressed as the means ± standard error (SE). Statistical analysis was performed using the statistical analysis program SPSS 13.0 (SSPS, Chicago, IL, USA). p<0.05 was considered significant.
Results
Selecting the four plasmids
Four plasmids (shRNA1, shRNA2, shRNA3, shRNA4) were transfected into the hepatocytes respectively. The results showed that green fluorescence was strongest at 48h, as observed by fluorescence confocal microscopy. The SREBP-1c expression was significantly lower in the shRNA2 and shRNA1 treatment groups than in the control groups, and the shRNA2 was the lowest ( Fig. 1; p<0.05 ), so we used shRNA2 to continue our studies.
The optimum concentration of AD-GFP-SREBP-1c for infection
This study confirmed the optimum concentration of AD-GFP-SREBP-1c for infection by fluorescence confocal microscopy and flow cytometry. The infection efficiency of the hepatocytes was higher, and the apoptotic rate was lower when the MOI was 100; therefore, we ensured that all the samples were collected when the MOI was 100 ( Fig. 2; p<0.05) . 
The effect of low SREBP-1c expression on ACC expression
The mRNA and protein expression levels for ACC were significantly decreased in the bovine hepatocytes that were treated with AD-GFP-SREBP-1c (Fig. 3B, Fig. 4C; p<0.05 ).
The effects of low SREBP-1c expression on the expression and enzymatic activity of fatty acid oxidation enzymes
The mRNA expression levels of ACSL-1, CPT-I, CPT-П, and HADH increased significantly in bovine hepatocytes after being treated with AD-GFP-SREBP-1c (Fig. 3C, D, E, F; p<0.05) . We detected the enzymatic activities after infecting with AD-GFP-SREBP-1c, and the enzymatic activities of CPT-I, CPT-П, ACSL-1 and HADH increased significantly (Fig. 5A, B, C, D; p<0.05 ).
The effects of low SREBP-1c expression on the assembly and secretion of VLDL
The mRNA expression levels of ApoB, ApoE, and MTTP were significantly lower in the AD-GFP-SREBP-1c treatment groups than in the control and negative control groups (Fig.   Fig. 4 . The expression levels of SREBP-1c (Fig. 4B) , ACC (Fig. 4C) , and β-actin (Fig. 4A ) protein according to a western blot after infecting AD-GFP-SREBP-1c. Control (no infected), NC (negative control, empty adenovirus vector which has no SREBP-1c), AD-GFP-SREBP-1c (infected with the low expression adenovirus vector).
Fig. 5.
The enzymatic activity results for CPT-Ⅰ (Fig. 5A) , CPT-Ⅱ (Fig. 5B), HADH (Fig. 5C) , and ACSL-1 (Fig.  5D) were examined by ELISA. Control (no infected), NC (negative control, empty adenovirus vector which has no SREBP-1c), AD-GFP-SREBP-1c (infected with the low expression adenovirus vector). The values are the means ± SE (n=3). Compared with the control, the enzymatic activities have clearly changed (**p<0.01 or * p<0.05).
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3G, H, I; p<0.05).
In addition, the mRNA expression of LDLR was significantly higher in the AD-GFP-SREBP-1c treatment groups than in the control and negative control groups ( Fig. 3J ; p<0.05).
TG and VLDL contents
To confirm the effects of low SREBP-1c expression on the fatty acid metabolism in bovine hepatocytes, we detected the TG contents in hepatocytes and VLDL in the culture medium. The TG content was significantly lower in the AD-GFP-SREBP-1c treatment groups than in the control groups ( Fig. 6A; p<0.05) , and the VLDL content was also significantly lower than that of the control groups ( Fig. 6B; p<0.05 ).
Discussion
Fatty liver occurs in dairy cows during periods of elevated blood NEFA. Elevated blood NEFA levels are associated with NEB and hormonal changes at parturition. Overfeeding during the dry period leads to a deposition of body fat, and the dry matter intake (DMI) is beyond repair during the short postpartum period. The degree of lipid mobilization and NEB is worse, consequently, the incidence of fatty liver in overweight cows is higher. Fatty liver is a nutritional and metabolic disease, and it primarily occurs in high yield cows during the perinatal period, it is a high incidence disease and has an enormous influence on cows' health and productivity.
SREBP-1c is a subtype of SREBPs, and it is a key transcription factor that regulates intracellular lipid metabolism. Some studies have shown that SREBP-1c regulated the expression of lipid synthesis genes and then influenced hepatic lipid metabolism [10] . Studies have indicated that the overexpression of SREBP-1c could lead to a disorder in lipid metabolism, and then cause fat accumulation in non-adipose tissue such as the liver [11] . Fatty liver is characterized by insulin resistance (IR) and is associated with SREBP-1c. The liver volume increased 33% in rats with SREBP-1c over-expression, and the TG also clearly increased and leading to fatty liver. When SREBP-1c was overexpressed in transgenic mouse livers, fatty acid synthesis increased 26 times, and the synthesis of cholesterol increased 5 times [12] . The hepatic lipid metabolism of dairy cows is different from that of monogastric animals such as humans and mice. The regulation of SREBP-1c in the hepatic lipid metabolism of dairy cows may also be different [13] . Therefore, bovine hepatocytes were cultured and VLDL [29, 30] . MTTP is very important in the early stage of assembly of ApoB, and the MTTP combines with ApoB in the endoplasmic reticulum as a carrier, and is then transported outside the liver as a very low density lipoprotein [31] [32] [33] . MTTP expression decreased and was consistent with the change in ApoB. The TG and VLDL contents and the expression levels of ApoB, ApoE, MTTP and LDLR were detected. We found that the expression levels of ApoB, ApoE, and MTTP decreased, and LDLR was significantly elevated in the hepatocytes after decreasing the SREBP-1c expression. The elevated expression of LDLR could inhibit the ApoB secretion and regulate the assembly of VLDL by blocking the secretion of VLDL [34] . The accumulation of TG in the liver is the most direct cause of fatty liver. However, the most important reason for TG accumulation is increased fatty synthesis and reduced transfer out of the liver or reduced TG hydrolysis. VLDL is the most important form of transport TG, and the TG concentration may affect the VLDL content. In this study, the TG concentration in the hepatocytes was markedly reduced when the SREBP-1c expression was decreased, which may have been caused by the low expression of ApoB, ApoE, and MTTP. A reduction in the VLDL can decrease the TG accumulation and then potentially decrease the incidence of fatty liver.
In conclusion, low SREBP-1c expression decreased lipid synthesis and VLDL assembly, and increased lipid oxidation, thereby decreasing the TG content of hepatocytes.
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